ISIS EIF4E Rx + ISIS EIF4E Rx + ISIS EIF4E Rx + Prednisone + Docetaxel
Phase 1/2Completed 0 watching 0 views this week💤 Quiet
38
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Castrate-Resistant Prostate Cancer
Conditions
Castrate-Resistant Prostate Cancer
Trial Timeline
Nov 1, 2010 → Dec 1, 2013
NCT ID
NCT01234025About ISIS EIF4E Rx + ISIS EIF4E Rx + ISIS EIF4E Rx + Prednisone + Docetaxel
ISIS EIF4E Rx + ISIS EIF4E Rx + ISIS EIF4E Rx + Prednisone + Docetaxel is a phase 1/2 stage product being developed by Ionis Pharmaceuticals for Castrate-Resistant Prostate Cancer. The current trial status is completed. This product is registered under clinical trial identifier NCT01234025. Target conditions include Castrate-Resistant Prostate Cancer.
Hype Score Breakdown
Clinical
13
Activity
8
Company
7
Novelty
4
Community
3
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT01234025 | Phase 1/2 | Completed |
Competing Products
9 competing products in Castrate-Resistant Prostate Cancer
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| eFT508 | eFFECTOR Therapeutics | Phase 2 | 44 |
| AZD4635 + Durvalumab + Cabazitaxel | AstraZeneca | Phase 2 | 52 |
| Intermittent dosing of AZD5363 + Intermittent dosing of AZD5363 + Intermittent dosing of AZD5363 | AstraZeneca | Phase 1 | 33 |
| Part A: AZD8186 monotherapy + Part B: AZD8186 monotherapy + Part C1: Abiraterone acetate combination with AZD8186 + Part D1: AZD2014 combination with AZD8186 + Part D2 AZD2014 combination with AZD8186 + Part C2: Abiraterone acetate combination with AZD8186 | AstraZeneca | Phase 1 | 33 |
| BEZ235 + Prednisone + Abiraterone acetate | Novartis | Phase 1/2 | 41 |
| Atezolizumab + Radium-223 Dichloride | Roche | Phase 1 | 33 |
| Denosumab | Amgen | Phase 3 | 76 |
| Alobresib + Enzalutamide | Gilead Sciences | Phase 1/2 | 40 |
| custirsen sodium + isotonic, 0.9% sodium chloride + docetaxel + cabazitaxel + prednisone | Achieve Life Sciences | Phase 3 | 69 |